Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$81.28

0.42 (0.52%)

, ABT

Abbott

$43.50

0.53 (1.23%)

08:55
10/11/16
10/11
08:55
10/11/16
08:55

Cowen says St. Jude advisory common for the industry

While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

STJ

Acquired by ABT

$81.28

0.42 (0.52%)

ABT

Abbott

$43.50

0.53 (1.23%)

  • 19

    Oct

  • 19

    Oct

  • 26

    Oct

  • 06

    Nov

STJ Acquired by ABT
$81.28

0.42 (0.52%)

08/29/16
RHCO
08/29/16
NO CHANGE
RHCO
St. Jude Medical deal unlikely to be impacted by negative report, says SunTrust
After Muddy Waters discussed weaknesses in St. Jude's (STJ) cybersecurity ecosystem, SunTrust analyst Bruce Nudell does not expect the company's CRM products to be recalled and does not believe that its Merlin remote monitoring system will be disabled. Consequently, the analyst does not expect the company's pending acquisition by Abbott (ABT) to be terminated or re-priced. The analyst keeps a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
ABT Abbott
$43.50

0.53 (1.23%)

09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.

TODAY'S FREE FLY STORIES

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:38
02/27/17
02/27
19:38
02/27/17
19:38
Hot Stocks
Priceline: 'Solid start' to Q1, shift of Easter into Q2 to pressure some metrics »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

ROYT

Pacific Coast Oil

$1.94

0.02 (1.04%)

19:33
02/27/17
02/27
19:33
02/27/17
19:33
Downgrade
Pacific Coast Oil rating change  »

Pacific Coast Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

, BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

19:28
02/27/17
02/27
19:28
02/27/17
19:28
Hot Stocks
Court rules in favor of Arctic Cat in Bombardier patent litigation »

Arctic Cat (ACAT)…

ACAT

Arctic Cat

$18.49

-0.01 (-0.05%)

BDRBF

Bombardier

$1.81

-0.03 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:17
02/27/17
02/27
19:17
02/27/17
19:17
Hot Stocks
Priceline CFO: 'Hopeful' on promised Trump tax reform »

During the company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PCLN

Priceline

$1,632.01

0.39 (0.02%)

19:16
02/27/17
02/27
19:16
02/27/17
19:16
Hot Stocks
Priceline says board approved new $2B buyback authorization »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

19:09
02/27/17
02/27
19:09
02/27/17
19:09
Hot Stocks
vTv Therapeutics sees reporting topline data from STEADFAST Part A in early 2018 »

Says STEADFAST Part B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:55
02/27/17
02/27
18:55
02/27/17
18:55
Earnings
AAC Holdings sees FY17 adjusted EPS 50c-58c, consensus 72c »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CSX

CSX

$48.71

0.23 (0.47%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
CSX sees at least $160M charge from 'management streamlining' plan »

CSX disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$76.45

0.15 (0.20%)

18:54
02/27/17
02/27
18:54
02/27/17
18:54
Hot Stocks
Iowa American Water rate adjustment approved by IUB »

Following a 10-month…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:53
02/27/17
02/27
18:53
02/27/17
18:53
Hot Stocks
AAC Holdings sees over $8M in savings in 2017 from workforce reduction »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MORN

Morningstar

$81.62

-0.1 (-0.12%)

18:52
02/27/17
02/27
18:52
02/27/17
18:52
Hot Stocks
Morningstar CFO Stephane Biehler to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$248.60

3.55 (1.45%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Hot Stocks
Northrop Grumman appoints Pamiljans as aerospace systems president »

The board of Northrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAC

AAC Holdings

$7.59

0.01 (0.13%)

18:51
02/27/17
02/27
18:51
02/27/17
18:51
Earnings
AAC Holdings reports Q4 adjusted EPS 15c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MS

Morgan Stanley

$45.84

0.31 (0.68%)

18:48
02/27/17
02/27
18:48
02/27/17
18:48
Hot Stocks
Morgan Stanley discloses erroneous client tax reporting, says in talks with IRS »

Morgan Stanley disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

MS

Morgan Stanley

$45.84

0.31 (0.68%)

, BK

BNY Mellon

$47.11

0.02 (0.04%)

18:47
02/27/17
02/27
18:47
02/27/17
18:47
Hot Stocks
Morgan Stanley says reached settlement in New York Mellon dispute »

Morgan Stanley (MS)…

MS

Morgan Stanley

$45.84

0.31 (0.68%)

BK

BNY Mellon

$47.11

0.02 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

OLN

Olin Corp.

$30.90

0.1 (0.32%)

18:41
02/27/17
02/27
18:41
02/27/17
18:41
Hot Stocks
Olin Corp. chairman Joseph Rupp to retire »

Olin Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 01

    Mar

  • 14

    Mar

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:35
02/27/17
02/27
18:35
02/27/17
18:35
Hot Stocks
Wheeler REIT revises dividend payment schedule »

Effective April 1, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:34
02/27/17
02/27
18:34
02/27/17
18:34
Hot Stocks
Ashford Hospitality: FelCor statements on proposal 'misguided and misleading' »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

, FCH

Felcor Lodging

$7.33

0.25 (3.53%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Ashford Hospitality Trust acknowledges Land and Buildings endorsement »

Ashford Hospitality Trust…

AHT

Ashford Hospitality

$6.80

0.39 (6.08%)

FCH

Felcor Lodging

$7.33

0.25 (3.53%)

AINC

Ashford

$56.72

-0.28 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHLR

Wheeler REIT

$1.83

0.06 (3.39%)

18:28
02/27/17
02/27
18:28
02/27/17
18:28
Hot Stocks
Wheeler REIT announces 1-for-8 reverse stock split »

The Company's Board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

VTVT

vTv Therapeutics

$6.14

0.45 (7.91%)

18:18
02/27/17
02/27
18:18
02/27/17
18:18
Earnings
vTv Therapeutics reports Q4 EPS (42c), consensus (44c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:10
02/27/17
02/27
18:10
02/27/17
18:10
Hot Stocks
Delek Logistics targets 10% annual increase in distribution through 2019 »

CEO Yemin concluded,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DKL

Delek Logistics

$31.20

0.65 (2.13%)

18:06
02/27/17
02/27
18:06
02/27/17
18:06
Earnings
Delek Logistics reports Q4 EPS 47c, consensus 48c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

DK

Delek US

$22.98

-0.21 (-0.91%)

18:06
02/27/17
02/27
18:06
02/27/17
18:06
Earnings
Delek US reports Q4 adjusted EPS (44c), consensus (55c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

KRA

Kraton Performance

$27.49

0.68 (2.54%)

18:01
02/27/17
02/27
18:01
02/27/17
18:01
Hot Stocks
Kraton Performance announces global Tall Oil Fatty Acids price increase »

Kraton announces a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 07

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.